Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated PatientsRitchell van Dams, Amar U. Kishan, Naomi Jiang et al.|International Journal of Radiation Oncology*Biology*Physics|2021Cited by 63
Initial clinical observations of intra- and interfractional motion variation in MR-guided lung SBRTDavid H. Thomas, Daniel A. Low, Anand P. Santhanam et al.|British Journal of Radiology|2017Cited by 62
A treatment planning comparison between modulated tri-cobalt-60 teletherapy and linear accelerator–based stereotactic body radiotherapy for central early-stage non−small cell lung cancerCatherine Merna, Percy Lee, Jean-Claude M. Rwigema et al.|Medical dosimetry|2016Cited by 37
<sup>177</sup> Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II StudyAmar U. Kishan, Jérémie Calais, Luca Valle et al.|Journal of Clinical Oncology|2025Cited by 24
Use of focal radiotherapy boost for prostate cancer: radiation oncologists’ perspectives and perceived barriers to implementationAllison Y. Zhong, Tyler M. Seibert, Asona Lui et al.|Radiation Oncology|2023Cited by 23